Importer of Controlled Substances; Notice of Registration, 7004 [E8-2141]
Download as PDF
<![CDATA[
7004
Federal Register / Vol. 73, No. 25 / Wednesday, February 6, 2008 / Notices
pwalker on PROD1PC71 with NOTICES
disposal. Conveyance of the identified
public land will be subject to valid
existing rights and encumbrances of
record, including but not limited to,
rights-of-way for roads and public
utilities. Conveyance of any mineral
interests pursuant to section 209 of the
FLPMA will be analyzed during
processing of the proposed sale.
On February 6, 2008, the abovedescribed land will be segregated from
appropriation under the public land
laws, including the mining laws, except
the sale provisions of the FLPMA. Until
completion of the sale, the BLM is no
longer accepting land use applications
affecting the identified public land,
except applications for the amendment
of previously-filed right-of-way
applications or existing authorizations
to increase the term of the grants in
accordance with 43 CFR 2807.15 and
2886.15. The segregative effect will
terminate upon issuance of a patent,
publication in the Federal Register of a
termination of the segregation, or
February 8, 2010, unless extended by
the BLM State Director in accordance
with 43 CFR 2711.1–2(d) prior to the
termination date.
Public Comments
For a period until March 24, 2008,
interested parties and the general public
may submit in writing any comments
concerning the land being considered
for sale, including notification of any
encumbrances or other claims relating
to the identified land, to Field Manager,
BLM Coeur d’Alene Field Office, at the
above address. In order to ensure
consideration in the environmental
analysis of the proposed sale, comments
must be in writing and postmarked or
delivered within 45 days of the initial
date of publication of this Notice.
Comments transmitted via e-mail will
not be accepted. Comments, including
names and street addresses of
respondents, will be available for public
review at the BLM Coeur d’Alene Field
Office during regular business hours,
except holidays. Individual respondents
may request confidentiality. Before
including your address, phone number,
e-mail address, or other personal
identifying information in your
comment, you should be aware that
your entire comment-including your
personal identifying information-may be
made publicly available at any time.
While you can ask us in your comment
to withhold your personal identifying
information from public review, we
cannot guarantee that we will be able to
do so. If you wish to have your name or
address withheld from public disclosure
under the Freedom of Information Act,
you must state this prominently at the
VerDate Aug<31>2005
18:21 Feb 05, 2008
Jkt 214001
beginning of your comments. Any
determination by the BLM to release or
withhold the names and/or addresses of
those who comment will be made on a
case-by-case basis. Such requests will be
honored to the extent allowed by law.
The BLM will make available for public
review, in their entirety, all comments
submitted by businesses or
organizations, including comments by
individuals in their capacity as an
official or representative of a business or
organization.
(Authority: 43 CFR 2711.1–2)
Dated: January 22, 2008.
Eric R. Thomson,
Coeur d’Alene Field Manager.
[FR Doc. 08–485 Filed 2–5–08; 8:45am]
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substances
listed.
Dated: January 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–2141 Filed 2–5–08; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4310–GG–P
THE NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated March 22, 2007 and
published in the Federal Register on
March 29, 2007, (72 FR 14832), Roche
Diagnostics Operation, Inc., Attn:
Regulatory Compliance, 9115 Hauge
Road, Indianapolis, Indiana 46250,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Schedule
Lysergic acid diethylamide (7315)
Alphamethadol (9605) ..................
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
Ecgonine (9180) ...........................
Methadone (9250) ........................
Morphine (9300) ...........................
I
I
I
II
II
II
II
The company plans to import the
listed controlled substances for the
manufacture of diagnostic products for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Roche Diagnostics Operations, Inc. to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Roche Diagnostics
Operations, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
Meeting of National Council on the
Humanities
The National Endowment for
the Humanities.
ACTION: Notice of meeting.
AGENCY:
Pursuant to the provisions of the
Federal Advisory Committee Act (Pub.
L. 92–463, as amended) notice is hereby
given the National Council on the
Humanities will meet in Washington,
DC on February 21–22, 2008.
The purpose of the meeting is to
advise the Chairman of the National
Endowment for the Humanities with
respect to policies, programs, and
procedures for carrying out his
functions, and to review applications for
financial support from and gifts offered
to the Endowment and to make
recommendations thereon to the
Chairman.
The meeting will be held in the Old
Post Office Building, 1100 Pennsylvania
Avenue, NW., Washington, DC. A
portion of the morning and afternoon
sessions on February 21–22, 2008, will
not be open to the public pursuant to
subsections (c)(4), (c)(6) and (c)(9)(B) of
section 552b of Title 5, United States
Code because the Council will consider
information that may disclose: trade
secrets and commercial or financial
information obtained from a person and
privileged or confidential; information
of a personal nature the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy; and information the premature
disclosure of which would be likely to
significantly frustrate implementation of
proposed agency action. I have made
this determination under the authority
granted me by the Chairman’s
E:\FR\FM\06FEN1.SGM
06FEN1
]]>Agencies
[Federal Register Volume 73, Number 25 (Wednesday, February 6, 2008)]
[Notices]
[Page 7004]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-2141]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated March 22, 2007 and published in the Federal
Register on March 29, 2007, (72 FR 14832), Roche Diagnostics Operation,
Inc., Attn: Regulatory Compliance, 9115 Hauge Road, Indianapolis,
Indiana 46250, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of the basic
classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (7315).......... I
Alphamethadol (9605)....................... I
Tetrahydrocannabinols (7370)............... I
Cocaine (9041)............................. II
Ecgonine (9180)............................ II
Methadone (9250)........................... II
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
the manufacture of diagnostic products for distribution to its
customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the
registration of Roche Diagnostics Operations, Inc. to import the basic
class of controlled substance is consistent with the public interest
and with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971, at this time. DEA
has investigated Roche Diagnostics Operations, Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above named company is granted
registration as an importer of the basic class of controlled substances
listed.
Dated: January 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-2141 Filed 2-5-08; 8:45 am]
BILLING CODE 4410-09-P
